GuangYuYuan Chinese Herbal Medicine Co., Ltd. Secures Drug Registration Certificate for Subsidiary
GuangYuYuan Chinese Herbal Medicine Co., Ltd. (600771), a prominent player in the health care sector, has recently announced a significant development in its operations. On December 23, 2025, the company confirmed the acquisition of a drug registration certificate for one of its subsidiaries. This milestone underscores GuangYuYuan’s ongoing commitment to expanding its pharmaceutical offerings and enhancing its market presence.
Operating primarily in Xi’an, China, GuangYuYuan specializes in the development and manufacturing of a diverse range of pharmaceutical products. These include Chinese raw material medicines, Western raw material medicines, tablets, capsules, injections, and other drugs. The company also extends its services to advertising, further solidifying its role in the pharmaceutical industry.
Listed on the Shanghai Stock Exchange, GuangYuYuan has maintained a steady presence in the market since its Initial Public Offering on October 16, 1996. As of the latest trading session, the company’s stock closed at 19.24 CNY. Over the past 52 weeks, the stock has experienced fluctuations, reaching a high of 22.92 CNY on August 17, 2025, and a low of 16.21 CNY on April 6, 2025. These figures reflect a moderate range of price movement, indicative of the company’s resilience in a competitive market.
The acquisition of the drug registration certificate is a strategic move that is expected to bolster GuangYuYuan’s product portfolio and potentially drive future growth. This development is particularly noteworthy as it aligns with the company’s long-term objectives of innovation and expansion within the pharmaceutical sector.
For more information about GuangYuYuan Chinese Herbal Medicine Co., Ltd., stakeholders and interested parties can visit their official website at www.guangyuyuan.cn .
